Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)

Kalff, A; Khong, T; Ramachandran, M; Walker, P; Schwarer, A; Roberts, A W; Campbell, P; Filshie, R; Norton, S; Reynolds, J; Young, M; Pierceall, W; Thakurta, A; Guo, M; Oppermann, U; Wang, M; Ren, Y; Kennedy, N; Parekh, S; Spencer, A

File(s) under permanent embargo

Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)

journal contribution

posted on 2021-01-01, 00:00 authored by A Kalff, T Khong, M Ramachandran, P Walker, A Schwarer, A W Roberts, P Campbell, R Filshie, S Norton, J Reynolds, M Young, W Pierceall, A Thakurta, M Guo, U Oppermann, M Wang, Y Ren, N Kennedy, S Parekh, A Spencer

Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)

History

Journal

Leukemia and Lymphoma

Volume

62

Issue

12

Pagination

2981 - 2991

Publisher

Taylor & Francis

Location

Abingdon, Eng.

Publisher DOI

https://doi.org/10.1080/10428194.2021.1948030

ISSN

1042-8194

eISSN

1029-2403

Language

eng

Author URL

https://www.ncbi.nlm.nih.gov/pubmed/34263697

Publication classification

C1 Refereed article in a scholarly journal

Usage metrics

Keywords

cereblon pathway lenalidomide maintenance mass cytometry Myeloma

File(s) under permanent embargo

Cereblon pathway biomarkers and immune profiles in patients with myeloma receiving post-ASCT lenalidomide maintenance (LEOPARD)

History

Journal

Volume

Issue

Pagination

Publisher

Location

Publisher DOI

ISSN

eISSN

Language

Author URL

Publication classification

Usage metrics

Categories

Keywords

Licence

Exports